Highlights and Quick Summary
- SG&A Expenses for the quarter ending June 30, 2023 was $5.53 Million (a -6.57% decrease compared to previous quarter)
- Year-over-year quarterly SG&A Expenses increased by 13.18%
- Annual SG&A Expenses for 2022 was $19 Million (a 71.72% increase from previous year)
- Annual SG&A Expenses for 2021 was $11.1 Million (a 342.83% increase from previous year)
- Annual SG&A Expenses for 2020 was $2.5 Million (a 129.41% increase from previous year)
- Twelve month SG&A Expenses ending June 30, 2023 was $21.5 Million (a 5.86% increase compared to previous quarter)
- Twelve month trailing SG&A Expenses increased by 21.81% year-over-year
Trailing SG&A Expenses for the last four month:
30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
---|---|---|---|
$21.5 Million | $20.3 Million | $19 Million | $17.6 Million |
Visit stockrow.com/DSGN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical SG&A Expenses of Design Therapeutics, Inc.
Most recent SG&A Expensesof DSGN including historical data for past 10 years.Interactive Chart of SG&A Expenses of Design Therapeutics, Inc.
Design Therapeutics, Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2023 | $5.53 | $5.92 | – | – | – |
2022 | $5.14 | $4.89 | $4.34 | $4.61 | $18.98 |
2021 | $3.79 | $2.8 | $2.66 | $1.81 | $11.05 |
2020 | $1.19 | $0.49 | $0.43 | $0.39 | $2.5 |
2019 | – | – | – | – | $1.09 |
Business Profile of Design Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology